Skip to content
MARKETS / NASDAQ / ABVC
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Abvc Biopharma, Inc. ABVC

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$296,000
▼ 41.9% YoY
$-7.9M
In brief

What this company does

ABVC (“we” or the “Company”) is an early-stage biotechnology company with a pipeline of seven new drugs and one medical device under development, all of which are licensed from related parties of the Company. As of the date of this Report, the Company’s revenue has come from outlicensing our intellectual properties and providing CDMO services. The Company focuses on developing a product pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. GMP Manufacturing ABVC owns a certified GMP manufacturing facility through BioKey that is qualified to deliver small quantities of drugs for use by its clients in clinical trials from Phase I to Phase III. The BioKey facility comprises a GMP suite, product development area, analytical laboratory, food processing area, caged GMP storage area receiving area and two warehouses.

Written from the business description in ABVC BioPharma, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.

Growth
USD 296,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.3 · Net income -7.9
20M40M-8M-16M201020122014201620182020202220242025
Compound annual growth
−32.7%
−9.3%
−40.1%
+22.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −9.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−2830 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -2416.0% · Net -2830.1%
-50000%201020122014201620182020202220242025
ROE
FY2025 · ROE -128.2%
-200%-400%-600%201020122014201620182020202220242025

Each USD of equity lost 128 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2023 · FCF -4.2
-4M201020122014201620182020202220242025

Total assetsUSD 21.1M
EquityUSD 11.1M
CashUSD 681,480.00
Gross debtUSD 755,512.00
Net debtUSD 74,032.00
Current ratio0.41×

Net debt stands at 1% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.0··0.10.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0··−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0········
Income tax $B0.0−0.00.00.00.0−0.0−0.0−0.00.00.0··0.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B··−0.0−0.0−0.0·······−0.0−0.0−0.0−0.0
EPS, diluted $−0.39−0.42−1.80−5.19−0.51−0.50−0.21−0.48−0.02−0.06−0.01−0.010.00−0.04−0.31−0.47
Dividend / sh $················
Payout %················
ROE %−128.2−352.7−334.8−275.0−209.1−644.5····−9.7·····
Shares out B0.030.010.010.000.020.020.020.010.210.210.170.000.050.010.010.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 1 divergences in 72 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 23 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image